| 6.04 -0.24 (-3.82%) | 10-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.29 | 1-year : | 9.12 |
| Resists | First : | 7.09 | Second : | 7.8 |
| Pivot price | 6.41 |
|||
| Supports | First : | 5.94 | Second : | 4.95 |
| MAs | MA(5) : | 6.12 |
MA(20) : | 6.63 |
| MA(100) : | 7.11 |
MA(250) : | 6.5  |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 15.9 |
D(3) : | 14.4 |
| RSI | RSI(14): 33.2 |
|||
| 52-week | High : | 9.53 | Low : | 4.73 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ AURA ] has closed above bottom band by 22.5%. Bollinger Bands are 5.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.3 - 6.33 | 6.33 - 6.36 |
| Low: | 5.92 - 5.96 | 5.96 - 5.99 |
| Close: | 5.98 - 6.04 | 6.04 - 6.1 |
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
Thu, 01 Oct 2026
Forbion Entities Reveal 5.1% Stake in Aura Biosciences via SEC Filing - kalkinemedia.com
Thu, 01 Oct 2026
Three entities report a passive stake above 5% in Aura Biosciences (AURA). - Stock Titan
Wed, 30 Sep 2026
Precision Trading with Aura Biosciences Inc. (AURA) Risk Zones - Stock Traders Daily
Wed, 02 Sep 2026
Aura Biosciences to Participate in Upcoming Investor Conference - Yahoo Finance
Tue, 01 Sep 2026
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Wed, 12 Aug 2026
Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 104 (M) |
| Shares Float | 80 (M) |
| Held by Insiders | 1.5 (%) |
| Held by Institutions | 94.3 (%) |
| Shares Short | 6,160 (K) |
| Shares Short P.Month | 5,610 (K) |
| EPS | -1.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.04 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -31.3 % |
| Return on Equity (ttm) | -53.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.33 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -103 (M) |
| Levered Free Cash Flow | -56 (M) |
| PE Ratio | -3.5 |
| PEG Ratio | 0 |
| Price to Book value | 1.98 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|